ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial

Yang, Yunpeng; Min, Jie; Yang, Nong; Yu, Qitao; Cheng, Ying; Zhao, Yanqiu; Li, Manxiang; Chen, Hong; Ren, Shouan; Zhou, Jianying; Zhuang, Wu; Qin, Xintian; Cao, Lejie; Yu, Yan; Zhang, Jian; He, Jianxing; Feng, Jifeng; Yu, Hao; Zhang, Li*; Fang, Wenfeng*广东药学院; 广州医学院; 哈尔滨医科大学; 浙江大学; 郑州大学; 西安交通大学; 中山大学; 1
Signal Transduction and Targeted Therapy2023-8-14DOI: 10.1038/s41392-023-01538-w
19阅读
引用收藏
分享

摘要

Anaplastic lymphoma kinase (ALK) rearrangements are present in about 5-6% of non-small cell lung cancer (NSCLC) cases and associated with increased risks of central nervous system (CNS) involvement. Envonalkib, a novel ALK inhibitor, demonstrated promising anti-tumor activity and safety in advanced ALK-positive NSCLC in the first-in-human phase I study. This phase III trial (ClinicalTrials.gov NCT04009317) investigated the efficacy and safety of first-line envonalkib in advanced ALK-positive NSCLC cases. Totally 264 participants were randomized 1:1 to receive envonalkib (n = 131) or crizotinib (n = 133). Median independent review committee (IRC)-assessed progression-free survival (PFS) times were 24.87 (95% confidence interval [CI]: 15.64-30.36) and 11.60 (95% CI: 8.28-13.73) months in the envonalkib and crizotinib groups, respectively (hazard ratio [HR] = 0.47, 95% CI: 0.34-0.64, p < 0.0001). IRC-assessed confirmed objective response rate (ORR) was higher (81.68% vs. 70.68%, p = 0.056) and duration of response was longer (median, 25.79 [95% CI, 16.53-29.47] vs. 11.14 [95% CI, 9.23-16.59] months, p = 0.0003) in the envonalkib group compared with the crizotinib group. In participants with baseline brain target lesions, IRC-assessed CNS-ORR was improved with envonalkib compared with crizotinib (78.95% vs. 23.81%). Overall survival (OS) data were immature, and median OS was not reached in either group (HR = 0.84, 95% CI: 0.48-1.47, p = 0.5741). The 12-month OS rates were 90.6% (95% CI, 84.0%-94.5%) and 89.4% (95% CI, 82.8%-93.6%) in the envonalkib and crizotinib groups, respectively. Grade & GE;3 treatment-related adverse events were observed in 55.73% and 42.86% of participants in the envonalkib and crizotinib groups, respectively. Envonalkib significantly improved PFS and delayed brain metastasis progression in advanced ALK-positive NSCLC.

学科与关键词

关键词
PREFERRED 1ST-LINE OPTIONLORLATINIBINHIBITORSURVIVALNSCLC
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Signal Transduction and Targeted Therapy
发表日期
2023-08-14
卷期
第 8 卷, 第 1 期
页码
301
DOI
10.1038/s41392-023-01538-w
期刊收录
CAST-L
成果收录
SCIE
资助标注
National Natural Science Foundation Project of China [82072558]

作者

  • Y

    Yang, Yunpeng (第一作者)

    sun yat sen univ

  • M

    Min, Jie

    2

查看全部 20 位作者收起作者
  • Y

    Yang, Nong

    hunan canc hosp

  • Y

    Yu, Qitao

    guangxi med univ

  • C

    Cheng, Ying

    jilin prov canc hosp

  • Z

    Zhao, Yanqiu

    zhengzhou univ

  • L

    Li, Manxiang

    1 · xi an jiao tong univ

  • C

    Chen, Hong

    1 · chongqing med univ

  • R

    Ren, Shouan

    1 · shanxi med univ

  • Z

    Zhou, Jianying

    1 · zhejiang univ

  • Z

    Zhuang, Wu

    fujian canc hosp

  • Q

    Qin, Xintian

    1 · guangdong pharmaceut univ

  • C

    Cao, Lejie

    anhui prov hosp

  • Y

    Yu, Yan

    harbin med univ

  • Z

    Zhang, Jian

    1

  • H

    He, Jianxing

    1 · guangzhou med univ

  • F

    Feng, Jifeng

    jiangsu inst canc res · nanjing med univ

  • Y

    Yu, Hao

    nanjing med univ

  • Z

    Zhang, Li (通讯)

    sun yat sen univ

  • F

    Fang, Wenfeng (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417